Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000898432-25-000809
Filing Date
2025-10-07
Accepted
2025-10-07 19:51:18
Documents
7

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8237
2 PLEDGE AND SECURITY AGREEMENT, DATED AS OF OCTOBER 3, 2025, BY AND BETWEEN SHIVK exh99-5.htm EX-99.5 126233
3 ISSUER LETTER AGREEMENT, DATED AS OF OCTOBER 3, 2025, BY AND BETWEEN SHIVKAN AND exh99-6.htm EX-99.6 34295
4 image01.jpg GRAPHIC 27030
5 image02.jpg GRAPHIC 22696
6 image018.jpg GRAPHIC 7436
7 image019.jpg GRAPHIC 20131
  Complete submission text file 0000898432-25-000809.txt   277040
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Subject) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90473 | Film No.: 251381048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AMNEAL PHARMACEUTICALS LLC 400 CROSSING BOULEVARD BRIDGEWATER CA 08807
Business Address
Patel Chintu (Filed by) CIK: 0001737428 (see all company filings)

Type: SCHEDULE 13D/A